Smile Invest, a European investment firm focused on advanced technologies, healthcare and life sciences, environment, and B2B services, has acquired BAP Medical, a leading developer, manufacturer and distributor of medical devices.
BAP Medical was founded in 2006 by Rob Hollweg and has since grown into a leading specialist in medical skincare. The company develops, produces and distributes medical devices for patients dealing with scars, burns, chronic skin conditions, allergies, difficult-to-heal wounds and ENT-conditions. Its brand portfolio, including Alhydran, widely valued in burn centres, and BAPSCARCARE and Scarban for professional scar care, is recognised by medical specialists for its strong scientific foundation. From its own production facility in Belgium, operating under the name ScarPro, BAP Medical reaches practitioners and patients in more than 70 countries through its own sales organisations in the Netherlands, Belgium, the United Kingdom, and a worldwide distribution network.
Rob Hollweg, CEO BAP Medical: “We are proud and pleased that BAP Medical has found a new partner in Smile Invest that fits perfectly with who we are and what we stand for. At BAP Medical, culture has always been of great importance: the human side, collaboration, taking responsibility and the feeling of being part of one team. Today we are active in the aftercare of burns and scars, chronic skin conditions, allergies, difficult-to-heal wounds and products for ear, nose and throat care. From this strong foundation, we want to continue to grow, innovate and capture new opportunities. With Smile Invest, a new chapter begins, one in which we can continue to build on BAP Medical's growth together, both within our home markets and through our worldwide distribution network. Always driven by the same conviction: developing medical products that genuinely add value for medical specialists, practitioners and patients.”
The IMAP Netherlands deal team, consisting of Ian Bussey, Indrajeet Mohite, Jonah van Ravenzwaaij, Mathijs van Styrum, and Soleil Gouveia advised the shareholders of BAP Medical throughout the transaction.
